Meeting
2023 ASCO Annual Meeting
ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.
Authors
Richard F. Riedel
Duke Cancer Institute, Duke University Medical Center, Durham, NC
Richard F. Riedel , Sant P. Chawla , Mihaela Druta , Robin Lewis Jones , Scott Schuetze , Joelle Lam , Dongliang Zhuang , James L. Freddo , Bonne J. Adams , Charles P. Theuer , Sandra P. D'Angelo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT 04480502
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS11583)
DOI
10.1200/JCO.2023.41.16_suppl.TPS11583
Abstract #
TPS11583
Poster Bd #
515a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
ENVASARC: A pivotal trial of envafolimab, and envafolimab in combination with ipilimumab, in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.
First Author: Sandra P. D'Angelo
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
First Author: Sylvie Lorenzen
Poster
2017 Gastrointestinal Cancers Symposium
Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.
First Author: Yelena Yuriy Janjigian